Clinical trials: Pancreatic Cancer Stage I
Metastatic Pancreatic Cancer
Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer
The purpose of this study is to determine whether combination of TS-1 and concurrent and short-course radiotherapy is feasible in metastatic pancreatic cancer.
- Trial name
- SR-GS (NCT01946646)
- Testing
- S-1-CCRT
- Where
- Taiwan
- Volunteers
- 10 people
- Sponsor
- National Taiwan University Hospital
Pancreatic Cancer
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using…
- Trial name
- NCT05723107
- Testing
- Chemotherapy, Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- NYU Langone Health
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor
- Trial name
- NCT06105021
- Testing
- AFNT-211
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Affini-T Therapeutics, Inc.
Pancreas Cancer, Metastatic Pancreatic Cancer
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
This is a Phase I/Ib trial, single-center, non-randomized, open-label study of Protein-bound Paclitaxel, Cisplatin, And Gemcitabine (GCN) Combined with Tumor Treatment Fields (TTF) and G+TTF maintenance therapy in patients with…
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
- Trial name
- NCT04605913
- Testing
- Modified GCN+TTF treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Mayo Clinic
Metastatic Pancreatic Ductal Adenocarcinoma
ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma
The investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- NCT06904378
- Testing
- ONT01, Gemcitabine, Nab paclitaxel
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Washington University School of Medicine
Pancreatic Carcinoma Stage I, Pancreatic Carcinoma Stage II
Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
The purpose of this study is to assess the safety and tolerability of CVac, an investigational cell therapy, in patients with resected stage I or II adenocarcinoma of the pancreas who have completed surgery with or without…
- Trial name
- NCT02310971
- Testing
- CVac
- Sponsor
- Prima BioMed Ltd
Pancreatic Cancer
Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with resected or locally…
- Trial name
- NCT00008099
- Testing
- MUC1 antigen/SB AS-2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pittsburgh
Pancreatic Cancer, Biliary Cancer
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
The purpose of this study is to find out what effects gemcitabine plus capecitabine has on patients with pancreatic or biliary cancer, and to determine the optimal dose that can be given safely of these two drugs together (called…
- Trial name
- NCT00626158
- Testing
- gemcitabine, capecitabine
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of California, San Francisco
Metastatic Pancreatic Cancer
Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
- Trial name
- NCT05766748
- Testing
- Azeliragon
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Cantex Pharmaceuticals
Pancreatic Neoplasms
Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas
The purpose of this trial is to determine the maximum tolerated dose and the dose-limiting toxicity of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine in patients with…
- Trial name
- NCT00220649
- Testing
- gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Pancreatic Cancer
Neoadjuvant Accelerated Short Course Radiation Therapy With Proton Beam and Capecitabine for Resectable Pancreatic Cancer
A standard treatment for pancreatic cancer is radiation therapy plus chemotherapy after surgery. Radiation therapy and chemotherapy are commonly given for up to six weeks.
- Trial name
- NCT00438256
- Testing
- Proton Beam Radiation, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Massachusetts General Hospital
Pancreatic Neoplasms, Pancreatic Cancer
Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer
This study assesses the safety and efficacy of RTA 402 in combination with gemcitabine in patients with unresectable pancreatic cancer.
- Trial name
- NCT00529113
- Testing
- Bardoxolone methyl, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Biogen
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Pancreatic Cancer, Gastric Cancer
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Background: A new cancer therapy involves taking white blood cells from a person, growing them in the lab, genetically modifying them, then giving them back to the person.
- Conditions
- Pancreatic Cancer, Gastric Cancer, Gastrointestinal Cancer, Colon Cancer
- Trial name
- NCT03190941
- Testing
- Cyclophosphamide, Fludarabine, Anti-KRAS G12V mTCR PBL
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating advanced solid tumors.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00066651
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Gemcitabine, Oxaliplatin and Capecitabine for Advanced Pancreatic Carcinoma
Gemcitabine is the mainstay of palliative chemotherapy for patients with advanced pancreatic cancer (APC). Recent randomized trials have shown increased clinical benefit with the addition of oxaliplatin and prolonged median…
- Trial name
- GEMOXEL (NCT00744640)
- Testing
- gemcitabine, oxaliplatin, capecitabine
- Where
- 8 sites in Switzerland
- Volunteers
- 46 people
- Sponsor
- University Hospital, Basel, Switzerland
Anal Cancer, Carcinoma of the Appendix
Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00654160
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Pancreatic Cancer
Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01416662
- Testing
- gemcitabine hydrochloride
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Pancreatic Cancer
AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
RATIONALE: AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00265876
- Testing
- AZD0530, gemcitabine hydrochloride
- Where
- 4 sites in Canada
- Volunteers
- 34 people
- Sponsor
- NCIC Clinical Trials Group
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
This study is a single-arm, phase I trial, up to 16 participants with resectable PDA. The study will examine the efficacy of the mutant IDH1 inhibitor ivosidenib, in conjunction with standard-of-care mFOLFIRINOX in the…
- Trial name
- NCT05209074
- Testing
- Ivosidenib, mFOLFIRINOX
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Case Comprehensive Cancer Center